HHS awards $126.5M for COVID-19 vaccine R&D, focusing on variant impact and novel assays

Contract Overview

Contract Amount: $126,485,055 ($126.5M)

Contractor: PPD Development LP

Awarding Agency: Department of Health and Human Services

Start Date: 2023-09-29

End Date: 2029-09-28

Contract Duration: 2,191 days

Daily Burn Rate: $57.7K/day

Competition Type: NOT COMPETED

Number of Offers Received: 1

Pricing Type: TIME AND MATERIALS

Sector: R&D

Official Description: ADVANCED RESEARCH AND DEVELOPMENT ACTIVITIES FOR NOVEL IMMUNOGENICITY ASSAYS AND SAMPLE COLLECTION TECHNOLOGIES AS PART OF BARDA?S CONTINUING SUPPORT FOR COVID-19 VACCINE DEVELOPMENT, ASSESSING IMPACT OF VARIANTS ON VACCINE IMMUNOGENICITY, AND ANALYZ

Place of Performance

Location: WILMINGTON, NEW HANOVER County, NORTH CAROLINA, 28401

State: North Carolina Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $126.5 million to PPD DEVELOPMENT LP for work described as: ADVANCED RESEARCH AND DEVELOPMENT ACTIVITIES FOR NOVEL IMMUNOGENICITY ASSAYS AND SAMPLE COLLECTION TECHNOLOGIES AS PART OF BARDA?S CONTINUING SUPPORT FOR COVID-19 VACCINE DEVELOPMENT, ASSESSING IMPACT OF VARIANTS ON VACCINE IMMUNOGENICITY, AND ANALYZ Key points: 1. Contract supports critical research into vaccine effectiveness against evolving COVID-19 variants. 2. Focus on developing advanced immunogenicity assays and sample collection technologies. 3. Long-term contract (5+ years) indicates sustained need for this research. 4. Awardee has a significant role in BARDA's ongoing COVID-19 preparedness efforts. 5. Research aims to improve future vaccine development and public health response. 6. Contract type (Time and Materials) may pose cost control challenges if not managed closely.

Value Assessment

Rating: good

The contract value of $126.5 million over approximately five years for advanced R&D in vaccine immunogenicity is substantial. Benchmarking this against similar large-scale biomedical research contracts within HHS or BARDA would be necessary for a precise value-for-money assessment. However, given the critical nature of COVID-19 research and the specialized expertise required, the pricing appears to be within a reasonable range for complex scientific endeavors. The Time and Materials pricing structure necessitates robust oversight to ensure efficient use of resources and prevent cost overruns.

Cost Per Unit: N/A

Competition Analysis

Competition Level: sole-source

This contract was awarded on a sole-source basis, indicating that PPD Development LP was the only entity deemed capable of performing the required advanced research and development activities. Sole-source awards are typically justified when there is a unique capability, a critical need for continuity with a previous effort, or when competition is not feasible. The lack of competition means that price discovery through market forces was not utilized, placing a greater emphasis on the government's negotiation and oversight capabilities.

Taxpayer Impact: A sole-source award means taxpayers did not benefit from competitive bidding, which could potentially lead to higher costs compared to a competed contract. Robust justification and negotiation are crucial to ensure fair pricing.

Public Impact

The primary beneficiaries are public health organizations and the scientific community, who will gain insights into vaccine efficacy against COVID-19 variants. Services delivered include advanced research and development for novel immunogenicity assays and sample collection technologies. The geographic impact is national, contributing to the U.S. response to the COVID-19 pandemic. Workforce implications include the utilization of highly specialized scientific and research personnel.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Time and Materials contract type can lead to cost overruns if not closely monitored.
Sole-source award limits competitive pressure, potentially impacting cost-effectiveness.
Reliance on a single contractor for critical R&D may pose a risk if performance issues arise.

Positive Signals

Contract supports critical, ongoing research vital for public health preparedness.
Awardee has established expertise in the relevant scientific domain.
Long contract duration suggests a strategic, long-term investment in vaccine development.

Sector Analysis

This contract falls within the Research and Development in the Physical, Engineering, and Life Sciences sector, specifically focusing on biomedical research. The market for such specialized R&D is characterized by high barriers to entry due to the need for advanced scientific expertise, specialized facilities, and regulatory compliance. Comparable spending in this area is often project-specific and driven by urgent public health needs, such as pandemic response. BARDA (Biomedical Advanced Research and Development Authority) is a key player in funding such critical research.

Small Business Impact

This contract does not appear to involve small business set-asides, as indicated by the 'sb': false parameter. The prime contractor, PPD Development LP, is a large entity. There is no explicit information regarding subcontracting plans for small businesses within the provided data. Therefore, the direct impact on the small business ecosystem from this specific award is likely minimal, though large prime contractors may engage small businesses in their supply chains.

Oversight & Accountability

Oversight for this contract will be managed by the Department of Health and Human Services, specifically the Office of Assistant Secretary for Preparedness and Response (ASPR). As a Time and Materials contract, rigorous monitoring of labor hours, material costs, and progress against research milestones will be essential. Transparency is expected through regular reporting requirements. The Inspector General's office within HHS would have jurisdiction for audits and investigations if any issues of fraud, waste, or abuse arise.

Related Government Programs

COVID-19 Vaccine Development Programs
Biomedical Advanced Research and Development Authority (BARDA) Contracts
Immunogenicity Assay Development
Vaccine Efficacy Research
Public Health Emergency Preparedness

Risk Flags

Potential for cost overruns due to Time and Materials contract type.
Lack of competition may impact overall value for money.
Reliance on a single contractor for critical R&D.

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $126.5 million to PPD DEVELOPMENT LP. ADVANCED RESEARCH AND DEVELOPMENT ACTIVITIES FOR NOVEL IMMUNOGENICITY ASSAYS AND SAMPLE COLLECTION TECHNOLOGIES AS PART OF BARDA?S CONTINUING SUPPORT FOR COVID-19 VACCINE DEVELOPMENT, ASSESSING IMPACT OF VARIANTS ON VACCINE IMMUNOGENICITY, AND ANALYZ

Who is the contractor on this award?

The obligated recipient is PPD DEVELOPMENT LP.

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (Office of Assistant Secretary for Preparedness and Response).

What is the total obligated amount?

The obligated amount is $126.5 million.

What is the period of performance?

Start: 2023-09-29. End: 2029-09-28.

What is the track record of PPD Development LP in performing similar advanced R&D contracts for the government?

PPD Development LP, now part of Thermo Fisher Scientific, has a substantial history of performing complex research and development services, including clinical trials and laboratory services, for government agencies. Their expertise spans various therapeutic areas and includes work on infectious diseases. While specific details on prior BARDA contracts for COVID-19 vaccine R&D are not provided in this snippet, their general capabilities suggest they are well-equipped for this type of work. A deeper dive into their contract performance history, including any past performance evaluations or awards, would provide a more comprehensive understanding of their reliability and success in similar government engagements.

How does the $126.5 million contract value compare to other BARDA investments in COVID-19 vaccine R&D?

The $126.5 million award represents a significant investment, reflecting the complexity and duration of the research into novel immunogenicity assays and variant impact. BARDA has funded numerous projects related to COVID-19 countermeasures, including vaccine development, diagnostics, and therapeutics, with funding levels varying widely based on project scope and phase. While this specific amount is substantial, it is not unusual for advanced R&D efforts requiring specialized expertise and long-term commitment. Comparing it directly requires analyzing the scope and objectives of other BARDA awards; however, it aligns with the scale of investment needed for critical pandemic preparedness research.

What are the primary risks associated with a sole-source, Time and Materials contract for advanced R&D?

The primary risks associated with this contract structure are twofold. Firstly, the sole-source nature means the government did not benefit from competitive pricing, potentially leading to a higher cost than if multiple bidders had competed. This necessitates strong negotiation and oversight. Secondly, the Time and Materials (T&M) pricing model, while flexible for R&D where scope can evolve, carries inherent risks of cost escalation if not meticulously managed. Uncontrolled labor hours or material costs can significantly inflate the total expenditure. Effective risk mitigation requires stringent monitoring of contractor performance, regular reviews of expenditures, and clear communication channels to manage scope changes.

How will the success of this contract contribute to future pandemic preparedness?

The success of this contract is crucial for future pandemic preparedness by advancing our understanding of how viral variants impact vaccine effectiveness and by developing more sophisticated tools to measure immune responses. Novel immunogenicity assays can provide faster, more accurate assessments of vaccine performance, enabling quicker decisions on booster shots or vaccine updates. Improved sample collection technologies can streamline the research process. Ultimately, the knowledge and tools generated will enhance the ability of agencies like BARDA to rapidly develop and deploy effective countermeasures against emerging infectious diseases, reducing the impact of future outbreaks.

What is the historical spending trend for similar R&D activities within HHS or BARDA?

Historical spending trends for R&D activities within HHS and BARDA, particularly concerning infectious diseases and vaccine development, have seen significant fluctuations. There was a notable surge in funding and contract awards related to COVID-19 countermeasures starting in 2020. Prior to the pandemic, BARDA's budget focused on a broader range of threats, with investments in areas like influenza, chemical/biological threats, and emerging infectious diseases. The scale of spending on COVID-19 R&D, including contracts like this one, represents a substantial increase driven by the urgent public health crisis. Analyzing historical data would show a baseline level of investment in preparedness R&D, punctuated by major escalations during declared emergencies.

Industry Classification

NAICS: Professional, Scientific, and Technical Services › Scientific Research and Development Services › Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Product/Service Code: RESEARCH AND DEVELOPMENT › N – Health R&D Services

Competition & Pricing

Extent Competed: NOT COMPETED

Solicitation Procedures: ONLY ONE SOURCE

Offers Received: 1

Pricing Type: TIME AND MATERIALS (Y)

Evaluated Preference: NONE

Contractor Details

Address: 929 N FRONT ST, WILMINGTON, NC, 28401

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Not Designated a Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $126,485,055

Exercised Options: $126,485,055

Current Obligation: $126,485,055

Actual Outlays: $23,770,106

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES PROCEDURES NOT USED

Cost or Pricing Data: NO

Timeline